TY - JOUR T1 - Real-time surveillance of international SARS-CoV-2 prevalence using systematic traveller arrival screening JF - medRxiv DO - 10.1101/2022.10.12.22280928 SP - 2022.10.12.22280928 AU - Adam J Kucharski AU - Kiyojiken Chung AU - Maite Aubry AU - Iotefa Teiti AU - Anita Teissier AU - Vaea Richard AU - Timothy W Russell AU - Raphaƫlle Bos AU - Sophie Olivier AU - Van-Mai Cao-Lormeau Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/10/13/2022.10.12.22280928.abstract N2 - Background Effective COVID-19 response relies on good knowledge of infection dynamics, but owing to under-ascertainment and delays in symptom-based reporting, obtaining reliable infection data has typically required large dedicated local population studies. Although many countries implemented SARS-CoV-2 testing among travellers, interpretation of arrival testing data has typically been challenging because arrival testing data were rarely reported systematically, and pre-departure testing was often in place as well, leading to non-representative infection status among arrivals.Methods In French Polynesia, testing data were reported systematically with enforced pre-departure testing type and timing, making it possible to adjust for non-representative infection status among arrivals. Combining statistical models of PCR positivity with data on international travel protocols, we reconstructed estimates of prevalence at departure using only testing data from arrivals. We then applied this estimation approach to the USA and France, using data from over 220,000 tests from travellers arriving into French Polynesia between July 2020 and March 2022.Findings We estimated a peak infection prevalence at departure of 2.8% (2.3-3.6%) in France and 1.1% (0.81-3.1%) in the USA in late 2020/early 2021, with prevalence of 5.4% (4.8-6.1%) and 5.5% (4.6-6.6%) respectively estimated for the Omicron BA.1 waves in early 2022. We found that our infection estimates were a leading indicator of later reported case dynamics, as well as being consistent with subsequent observed changes in seroprevalence over time.Interpretation As well as elucidating previously unmeasured infection dynamics in these countries, our analysis provides a proof-of-concept for scalable tracking of global infections during future pandemics.Funding Wellcome (206250/Z/17/Z)Competing Interest StatementThe authors have declared no competing interest.Funding StatementAK was funded by Wellcome (206250/Z/17/Z)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Communication of data from the surveillance system was approved by Comite d'ethique de la Polynesie francaise (ref Avis no. 90 CEPF 15_06_2021). Secondary data analysis was approved by the LSHTM Observational Research Ethics Committee (ref 28129).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code and data are available at: https://github.com/institutlouismalarde/covid-travel-testing ER -